FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

PolyPid NDA Accepted for Preventing Surgical Site Infection

FDA accepts for priority review a PolyPid NDA for D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal...

latest-news-card-1
FDA General

FDA Posts User Fee Rates for FY 2027

FDA posts the following user fee rates for medical product programs for fiscal year 2027.

latest-news-card-1
Human Drugs

9 Items on Bentley Laboratories FDA-483

FDA releases the form FDA-483 with nine observations from an inspection at the Edison, NJ-based Bentley Laboratories over-the-counter drug manufacturi...

latest-news-card-1
Medical Devices

Resmed Class 1 Recall of Astral Ventilators

Resmed recalls its Astral 100/150 ventilator system due to the potential for a supercapacitor electrolyte leakage on the printed circuit board assembl...

latest-news-card-1
FDA General

Dr. Oz Emerges as Potential Successor to RFK Jr. at HHS, Report Says

Bloomberg reports that Centers for Medicare & Medicaid Services head Mehmet Oz is increasingly viewed inside the Trump administration as the leading c...

latest-news-card-1
Human Drugs

Dr. Reddys Gets FDA-483 After Pre-Approval Inspection

FDA issues Dr. Reddys a three-observation Form FDA-483 following a pre-approval inspection and Good Manufacturing Practices inspection at the companys...

latest-news-card-1
Medical Devices

FDA De Novo OK for CaRi-Heart Coronary Inflammation Technology

FDA grants de novo authorization for Caristo Diagnostics CaRi-Heart coronary inflammation technology.

latest-news-card-1
Biologics

FDA Panel Votes Down Capricor's Duchenne Cell Therapy

An FDA advisory committee votes against recommending approval for Capricor Therapeutics' investigational cell therapy deramiocel, for treating cardiom...

latest-news-card-1
Human Drugs

New Effectiveness Evidence Requirements Analyzed

Two Latham Watkins attorneys analyze a revised FDA draft guidance on demonstrating substantial evidence of effectiveness in drug and biologic trials a...

Human Drugs

Allure Labs FDA-483 Out

FDA releases the form FDA-483 with three observations from an inspection at the Hayward, CA-based Allure Labs drug manufacturing facility.